Differentiation of neoantigen-reactive CD8 T cells in tumors from patients with mismatch repair-proficient colorectal cancers 4297

Abstract Description While the phenotype of neoantigen-reactive CD8 T cells in solid tumors has been identified by us and others, little is known about their differentiation in mismatch repair-proficient (MMR-p) colorectal cancers (CRC). To address that, we analyzed paired adjacent normal colon (NC) and primary tumors from patients with MMR-p CRC. Flow cytometry analysis showed a higher T-cell infiltration in tumors, with an enrichment in CD8 T cells. Both, NC and tumor contained a population of CD39+CD103 + (DP) CD8 T cells, a phenotype reminiscent of tumor-reactive T cells. Yet, DP CD8 T cells from the NC lacked PD-1 and Ki-67. To uncover the differentiation of tumor-reactive DP CD8 T cells, we performed scRNA-seq and scTCR-seq on paired NC and tumor from five patients. Using gene expression and RNA velocity, our analysis revealed that tumor-infiltrating DP CD8 T cells (DP CD8 TILs) undergo a linear progression toward an exhausted state and acquire a cytotoxic potential. Neoantigen discovery on three patients identified neoantigens recognized by DP CD8 TILs. The same neoantigens were also recognized by memory CD8 T cells in the blood at time of surgery, albeit at very low frequencies. TCR sequencing of the neoantigen-reactive T cells confirmed their DP CD8 nature but highlighted variability in their differentiation status. This work demonstrates the existence of neoantigen-reactive T cells in the blood and tumor of patients with MMR-p CRC which could be harnessed to promote tumor control. Funding Sources Supported by the Providence Portland Medical Foundation. Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)

Authors

Institutions

Publication Details

Journal
The Journal of Immunology
Published
2025-11-01
DOI
https://doi.org/10.1093/jimmun/vkaf283.1997
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Differentiation of neoantigen-reactive CD8 T cells in tumors from patients with mismatch repair-proficient colorectal cancers 4297

Olivier Fesneau, Thomas Duhen, Tanisha Christie, Venkatesh Rajamanickam et al.
The Journal of Immunology
Cancer Immunotherapy and Biomarkers
article

Differentiation of neoantigen-reactive CD8 T cells in tumors from patients with mismatch repair-proficient colorectal cancers 4297

Olivier Fesneau, Thomas Duhen, Tanisha Christie, Venkatesh Rajamanickam, Yoshinobu Koguchi, Kimberly Samson, Wesley Rosales
article en

Abstract

Abstract Description While the phenotype of neoantigen-reactive CD8 T cells in solid tumors has been identified by us and others, little is known about their differentiation in mismatch repair-proficient (MMR-p) colorectal cancers (CRC). To address that, we analyzed paired adjacent normal colon (NC) and primary tumors from patients with MMR-p CRC. Flow cytometry analysis showed a higher T-cell infiltration in tumors, with an enrichment in CD8 T cells. Both, NC and tumor contained a population of CD39+CD103 + (DP) CD8 T cells, a phenotype reminiscent of tumor-reactive T cells. Yet, DP CD8 T cells from the NC lacked PD-1 and Ki-67. To uncover the differentiation of tumor-reactive DP CD8 T cells, we performed scRNA-seq and scTCR-seq on paired NC and tumor from five patients. Using gene expression and RNA velocity, our analysis revealed that tumor-infiltrating DP CD8 T cells (DP CD8 TILs) undergo a linear progression toward an exhausted state and acquire a cytotoxic potential. Neoantigen discovery on three patients identified neoantigens recognized by DP CD8 TILs. The same neoantigens were also recognized by memory CD8 T cells in the blood at time of surgery, albeit at very low frequencies. TCR sequencing of the neoantigen-reactive T cells confirmed their DP CD8 nature but highlighted variability in their differentiation status. This work demonstrates the existence of neoantigen-reactive T cells in the blood and tumor of patients with MMR-p CRC which could be harnessed to promote tumor control. Funding Sources Supported by the Providence Portland Medical Foundation. Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)

The Journal of ImmunologyVol. 214(Supplement_1)
Cancer Institute (WIA) (IN), Providence Portland Medical Center (US)
Openalex Percentile: Top 52%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.